Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pangaea OncologyXMAD:PANG 60 Cyclically Adjusted PS Ratio is 5.34 as of Aug. 05, 2026, which is 16% below its 10-year median of 6.39. GuruFocus rates XMAD:PANG with a GF Score™ of 60/100 and a GF Value™ of €2.19 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 135 Medical Diagnostics & Research companies, Pangaea Oncology ranks worse than 74.81% on this metric.
The historical rank and industry rank for Pangaea Oncology's Cyclically Adjusted PS Ratio or its related term are showing as below:
XMAD:PANG'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 5.17 Med: 6.39 Max: 7.83
Current: 5.4
During the past 13 years, Pangaea Oncology's highest Cyclically Adjusted PS Ratio was 7.83. The lowest was 5.17. And the median was 6.39.
XMAD:PANG's Cyclically Adjusted PS Ratio is ranked worse than 74.81% of 135
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.88
vs XMAD:PANG: 5.40
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Pangaea Oncology's adjusted revenue per share data of for the fiscal year that ended in Dec25 was €0.404. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €0.29 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Pangaea Oncology (XMAD:PANG) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Pangaea Oncology Cyclically Adjusted PS Ratio Related Terms
Pangaea Oncology Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Pangaea Oncology's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pangaea Oncology Cyclically Adjusted PS Ratio Chart
XMAD:PANG vs TMO, DHR, IDXX: Cyclically Adjusted PS Ratio Comparison
For the Diagnostics & Research subindustry, Pangaea Oncology's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pangaea Oncology Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pangaea Oncology's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Pangaea Oncology's Cyclically Adjusted PS Ratio falls into.
Pangaea Oncology Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Pangaea Oncology's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 5.34 mean?
Pangaea Oncology (XMAD:PANG) has a Cyclically Adjusted PS Ratio of 5.34 as of Aug. 05, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pangaea Oncology and its competitors. This is 16% below median its historical median of 6.39. Over the past decade, Pangaea Oncology's Cyclically Adjusted PS Ratio has ranged from 5.17 to 7.83. According to the industry distribution chart, Pangaea Oncology ranks #101 out of 135 companies in the Medical Diagnostics & Research industry, placing it in the top 74.8%.
Is Pangaea Oncology's Cyclically Adjusted PS Ratio too high?
Pangaea Oncology's current Cyclically Adjusted PS Ratio of 5.34 is 16% below median its 10-year median of 6.39. Over the past 10 years, this metric has ranged from a low of 5.17 to a high of 7.83. The Medical Diagnostics & Research industry median Cyclically Adjusted PS Ratio is 1.88. Pangaea Oncology's value of 5.34 is 184% above this industry median. Based on the distribution chart, Pangaea Oncology ranks #101 out of 135 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Pangaea Oncology has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pangaea Oncology's Cyclically Adjusted PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pangaea Oncology ranks #101 out of 135 companies for Cyclically Adjusted PS Ratio. This places Pangaea Oncology in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 1.88. Pangaea Oncology's value of 5.34 is 184% above this benchmark. Historically, Pangaea Oncology's own Cyclically Adjusted PS Ratio has ranged from 5.17 to 7.83 over the past decade. While the company's 10-year median is 6.39 vs. the industry median of 1.88, Pangaea Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Diagnostics & Research company?
The median Cyclically Adjusted PS Ratio among Medical Diagnostics & Research companies is 1.88, based on 135 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pangaea Oncology's current Cyclically Adjusted PS Ratio of 5.34 is 184% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pangaea Oncology and its competitors. For the Medical Diagnostics & Research industry, the median Cyclically Adjusted PS Ratio is 1.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pangaea Oncology's current Cyclically Adjusted PS Ratio is 5.34, which is 16% below median its own 10-year median of 6.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pangaea Oncology stock overvalued right now?
Based on GuruFocus' analysis, Pangaea Oncology (XMAD:PANG) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.19, compared to a current price of €1.55 — trading 29.2% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 5.34, which is 16% below median its 10-year median of 6.39 and 184% above the Medical Diagnostics & Research industry median of 1.88. Pangaea Oncology's overall GF Score™ is 60/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Pangaea Oncology (XMAD:PANG), the current Cyclically Adjusted PS Ratio is 5.34 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?
Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued.
The current stock price of €1.55 is trading 29.2% below its estimated GF Value™ of €2.19.
GuruFocus considers Pangaea Oncology to be Modestly Undervalued.
Key valuation signals for XMAD:PANG:
Cyclically Adjusted PS Ratio: 5.34 (16% below median its 10-year median of 6.39)
GF Value™: €2.19 vs. price of €1.55 (29.2% below fair value)
Industry Position: 184% above the Medical Diagnostics & Research median (#101 of 135)
No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
60GF Score
Get the complete analysis for XMAD:PANG
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PANG has been successfully added to your 
